Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY January 2024 slide deck - over 120 panc pts studied

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 24, 2024 2:03pm

149 Views

Post# 35949648

RE:RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

And this is just one of the many new things that I posted: ...

Reportedly the one year survival for Stage IV (advanced or metastatic) cancer patients is 8% which would mean that in ONCY's Phase 2 Goblet-1 pancreatic cancer cohort with 13 evaluable patients, only 1.04 patients should have reached the one year survival milestone.

However in October 2023 ONCY reported that the 12 month survival rate in the evaluated Stage IV patients was 46%, suggesting that 6 patients were still alive, thus surpassing Stage IV pancreatic cancer historical survival rates by 6 fold.

<< Previous

Bullboard Posts

Next >>

B2Gold stock buckles under news of labour strike in Mali